DR study: 25 year results

Article

Although there is a relatively high rate of diabetic retinopathy (DR) progressing to proliferative diabetic retinopathy (PDR), the level of PDR care available has improved, according to 25-year results of the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), published in the November issue of Ophthalmology.

Although there is a relatively high rate of diabetic retinopathy (DR) progressing to proliferative diabetic retinopathy (PDR), the level of PDR care available has improved, according to 25-year results of the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), published in the November issue of Ophthalmology.

Ronald Klein, MD, MPH of the Department of Ophthalmology and Visual Sciences at the University of Wisconsin School of Medicine and Public Health in Madison, US and colleagues conducted the population-based study of diabetic subjects (n=955) living in the Wisconsin area of the US. Participants took insulin, and had been diagnosed with Type 1 diabetes before 30 years of age. Baseline examinations were conducted between 1980 and 1982; follow-up visits were conducted at four, 10, 14 and 25 years, with 520 subjects completing the final follow-up.

At the final follow-up point, the rate of DR improvement was 18%; the cumulative rate of DR progression was 83%, and the rate of progression of DR to PDR was 42%. Overall, factors found to influence (increase) DR progression were: severity of DR (less severe), gender (male), glycosylated haemoglobin level (high or increasing) and diastolic blood pressure (increasing before the four-year follow-up visit). Factors increasing PDR incidence were high body mass index (BMI) at baseline, high systolic blood pressure and glycosylated haemoglobin levels (particularly with an increase before the four year follow-up point), and proteinuria. The more recent the diabetes diagnosis, the lower the prevalence of PDR: this held true independently of the other PDR influential factors.

The researchers concluded that good glycaemic control reduced the risk of DR progression and, although the progression of DR across the study period was high, a more recent diabetes diagnosis decreased the prevalence of PDR, possibly due to an improvement in care over the study period.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
Related Content
© 2025 MJH Life Sciences

All rights reserved.